Euroopa Liit - rumeenia - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - agenți antitrombotici - possia, cu acidul acetilsalicilic (aas), este indicat pentru prevenirea evenimentelor atherothrombotic la pacienţii adulţi cu sindroame coronariene acute (angină instabilă, miocardic supradenivelarea st [nstemi] sau st-elevaţie infarct miocardic [stemi]); inclusiv pacienţii medical a reuşit, şi cei care sunt gestionate cu intervenţie coronariană percutanată (pci) sau arterelor coronare by-pass altoire (cabg).

Rumeenia - rumeenia - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - ropivacainum - sol. inj. - 10mg/ml - anestezice locale amide

Rumeenia - rumeenia - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - metoprololum - compr. cu elib. prel. - 100mg - medicamente betablocante betablocante selective

Rumeenia - rumeenia - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - metoprololum - compr. cu elib. prel. - 25mg - medicamente betablocante betablocante selective

Rumeenia - rumeenia - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - metoprololum - compr. cu elib. prel. - 50mg - medicamente betablocante betablocante selective

Euroopa Liit - rumeenia - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucemie, limfocitică, cronică, celule b - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Euroopa Liit - rumeenia - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agenți antineoplazici - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Euroopa Liit - rumeenia - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Euroopa Liit - rumeenia - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - seruri imune și imunoglobuline, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Rumeenia - rumeenia - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca uk limited - quetiapinum - compr. elib. prel. - 200mg - antipsihotice diazepine, oxazepine si tiazepine